Analysts’ Recommendations for AstraZeneca in 2Q17
Wall Street analysts expect AstraZeneca’s top line to fall ~9.5% to $5.1 billion in 2Q17, compared to $5.6 billion in 2Q16. Its earnings per share are expected to be $0.42 in 2Q17.
AstraZeneca’s (AZN) revenue is expected to fall 9.5% to $5.1 billion in 2Q17, compared to $5.6 billion in 2Q16.
AstraZeneca (AZN) is one of the largest pharmaceutical companies by revenue. The company operates in over 100 countries and deals with primary care and specialty care medicines.
Analysts expect Bristol-Myers Squibb’s (BMY) top line to rise 4.4% to ~$5.1 billion in 2Q17. They expect its earnings per share to be $0.74 in the quarter.
Bristol-Myers Squibb (BMY) is expected to report a rise of ~4.4% in its earnings to $5.1 billion for 2Q17 on July 27, 2017.
Headquartered in New York City, Bristol-Myers Squibb (BMY) is a leading American pharmaceutical company.
Wall Street analysts estimate that GSK’s top line will rise 11.4% to ~7.3 billion British pounds for 2Q17. Its EPS is expected come in at 0.26 pounds.
Analysts expect to see a growth of ~11.4% in GlaxoSmithKline’s (GSK) 2Q17 revenues, which are expected to total nearly 7.3 billion British pounds.
For 2Q17, analysts estimate that GSK’s revenues will rise ~11.4% to ~7.3 billion pounds, as compared to ~6.5 billion pounds for 2Q16.
On March 28, 2017, Vertex Pharmaceutical (VRTX) released data from a phase 3 trial, EVOLVE.
On March 29, 2017, Vertex Pharmaceuticals released positive data from two phase 3 trials, Evolve and Expand.
In 1Q17, Vertex Pharmaceuticals’ (VRTX) Kalydeco reported revenues close to $186 million, of which $102 million came from the US market.
ertex Pharmaceuticals’ Orkambi also secured U.S. Food and Drug Administration’s (or FDA) approval for CF patients in the age group of six to 11 years in September 2016.
Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.
Since July 17, 2017, Vertex Pharmaceuticals’ (VRTX) stock price has recorded a solid rise of around 26.3%.
Based on the recommendations of 19 brokerage firms in a Reuters survey, 68.0% rated Abbott Laboratories a “buy,” and 32.0% rated it a “hold.”
In 3Q17, the company’s operational sales growth is expected to be in the mid-single digits. Adjusted EPS is expected to be $0.64–$0.66.
Abbott completed the acquisition of St. Jude Medical in January 2017. It contributed significantly to its 2Q17 sales.
In 2Q17, Abbott Laboratories’ (ABT) Medical Devices segment reported a strong performance once again, registering a YoY sales growth of 89.2%.
On July 20, 2017, Abbott Laboratories (ABT) released its 2Q17 earnings. That day, ABT stock rose more than 4.0% from its closing price of $49.40 on July 19, 2017.